Genmab — AGM Information 2014

Apr 9, 2014

Company Announcement

-- At Genmab A/S’ Annual General Meeting held today on April 9, 2014 the
Annual Report for 2013 was approved
-- Discharge was given to the Board of Directors and the Executive Management
and the year’s profit was carried forward
-- All four members of the Board of Directors up for re-election were
re-elected
-- PricewaterhouseCoopers was re-elected as auditor of the Company
-- The proposal from the Board of Directors on general guidelines for
incentive-based remuneration, the proposal on repurchase of own shares, the
proposal on the Board of Directors’ remuneration for 2014 and the proposals
to amend Article 5 and Article 12 and to enter a new Article 18 in the
Articles of Association were adopted

Copenhagen, Denmark; April 9, 2014 – Genmab A/S (OMX: GEN) held its Annual
General Meeting, today at Tivoli Hotel & Congress Center, Copenhagen, Denmark.
At the meeting, Chairman of the Board of Directors Mr. Mats Pettersson gave –
on behalf of the Board of Directors – a report on the Company’s activities
during the past year. Chief Executive Officer Jan van de Winkel presented the
Company’s plans for the year ahead, and Chief Financial Officer David Eatwell
presented the Annual Report for 2013 endorsed by the auditors. The report was
approved and discharge was given to the Board of Directors and the Executive
Management.

It was decided that the year’s profit of DKK 125 million be carried forward by
transfer to accumulated deficit, as stated in the Annual Report.

Mats Pettersson, Dr. Anders Gersel Pedersen, Dr. Burton G. Malkiel and Mr. Hans
Henrik Munch-Jensen were re-elected to the Board of Directors for a one year
period.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected
as the Company’s auditor.

The General Meeting adopted the proposals from the Board of Directors, as
follows:

-- The proposal to adopt revised general guidelines for incentive-based
remuneration for the Board of Directors and the Executive Management.

-- The proposal to authorize the Board of Directors to allow for the Company
to repurchase own shares.

-- The proposal to adopt the Board of Directors’ remuneration for 2014.

-- The proposal to amend Article 5 of the Articles of Association to authorize
the Board of Directors to issue additional warrants - without pre-emption
rights for the existing shareholders - that give the right to subscribe up
to nominally DKK 500,000 shares in the Company to members of the Company’s
Board of Directors, the Company’s employees and consultants as well as
employees and consultants of the Company’s subsidiaries and to implement
the corresponding capital increases.

-- The proposal to amend Article 12 of the Articles of Association so that
the members of the Board of Directors elected by the General Meeting are
elected for a period which expires at the Annual General Meeting in the
Company in the first year after the year of their election.

-- The proposal to insert a new Article 18 in the Articles of Association
specifying
that the Annual Report shall be prepared in English only and, if decided by
the Board of Directors, in Danish
. As a result, the present Articles 18 and 19
of the Articles of Association
are renumbered 19 and 20.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™
and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 17
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark